Oxford Workshop to Establish an International 7T Glioma Magnetic Resonance Spectroscopy Network (GlioMaRS-Net)
Monday 16 November: 16:00-18:00 (UK London, GMT) 10:00-12:00 (UTC-6, Minnesota) 17:00-19:00 (UTC+1, Amsterdam)
Tuesday 17 November - Friday 20 November: 16:00-17:00 (UK London, GMT) 10:00-11:00 (UTC-6, Minnesota) 17:00-18:00 (UTC+1, Amsterdam)
Research into the role of ‘metabolic reprogramming’ and so-called ‘oncometabolites’ in cancer has seen a renaissance since the discovery that mutations in enzymes of the tricarboxylic acid (TCA) cycle can act as oncogenic drivers. Specifically, mutations in IDH1 or IDH2 and the resulting production of D-2-hydroxyglutarate (D2-HG) have come to define diffuse gliomas in young adults. This has opened up exciting new opportunities for noninvasive molecular glioma imaging with magnetic resonance spectroscopy (MRS) for diagnostics, trial recruitment and assessment of treatments. Further, a better understanding of the molecular mechanisms of mutation-specific metabolic reprogramming is likely to offer new drug targets.
These exciting developments have prompted us to convene an international workshop to explore how we could work together to drive forward progress in the field of glioma metabolomics for our patients.
- Find common ground on how MRS can contribute to ‘glioma precision medicine’ (and how it complements other imaging modalities)
- Explore what is needed to build a multi-centre consortium (e.g. protocol / data sharing)
- Identify scientific priorities at biochemical, cellular, tissue and whole brain imaging levels, and consider feasibility for integration of multimodal, multiscale data
- Identify funding possibilities
- Discuss options for writing a joint ‘perspectives’ paper about the potential of integrated MRS imaging in glioma precision medicine We encourage attendance by neurooncologists, neurosurgeons, biochemists and pathologists, in addition to those involved in MRS.
Monday: 16:00-18:00 (UK London, GMT) 10:00-12:00 (UTC-6, Minnesota) 17:00-19:00 (UTC+1, Amsterdam)
Tuesday-Friday :16:00-17:00 (UK London, GMT) 10:00-11:00 (UTC-6, Minnesota) 17:00-18:00 (UTC+1, Amsterdam)
The following daily session times are shown in UK London (GMT) time
Monday 16 November 2020
Hosts: Olaf Ansorge, Jannie Wijnen and Uzay Emir
16:00-16:10 Welcome, Introductions and Review of Meeting Goals
16:10 – 17:40 Plenary session: “Current status of glioma precision medicine”
16:10: Molecular neuropathology and classification of gliomas
Olaf Ansorge, MD, Consultant neuropathologist and Director of the Academic Unit of Neuropathology, Nuffield Department of Clinical Neurosciences, Oxford
16:40: 'Radiogenomics – MRI and MRS in brain cancer”'
Alexander Lin, PhD, Director of the Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School
17:10: 'IDH-mutated gliomas: clinical challenges and opportunities'
Clark C Chen, MD, PhD, Lyle French Chair in Neurosurgery and Department Head, University of Minnesota
17:40 -17:50: Proposal for a consensus ‘viewpoint’ paper and invitation to contribute
17:50 – 18:00: Instructions for workshops and closure
Tuesday 17 November 2020
Host: Uzay Emir
Co-host: Jannie Wijnen
16:00 -17:00: How to do Radiomics? from data acquisition to sharing
- Standardization of MRS protocols and analysis?
- Integration of in vivo MRS with ex vivo tissue metabolomics and genomics
- Data/method Sharing
Wednesday 18 November 2020
Hosts: Anja van der Kolk, Clark Chen
16:00-17:00: Clinical workflow and recruitment for clinical trials
- Patient recruitment
- Data sharing
- Embedding in clinical workflow
Thursday 19 November 2020
Host: Olaf Ansorge
Co-host: Alex Lin
16:00-17:00: Funding & Engagement with external parties
- Integration of in vivo MRS with other imaging modalities
- From basic science to drug development and engagement with pharma
- Engagement with MR vendors?
- (International) funding possibilities
Organization team reconvenes after the sessions to prepare summaries for Friday
Friday 20 November 2020
Host: Jannie Wijnen
Cohost: Evita Wiegers
16:00 -16:30: Summary of main findings of workshop
16:30 - 17:00: Discussion and plan for the way forward
Olaf Ansorge (on behalf of the organising committee)
Wellcome Centre for Integrative Neuroimaging,
Nuffield Department of Clinical Neurosciences,
University of Oxford, Oxford UK